{"id":14288,"url":"\/distributions\/14288\/click?bit=1&hash=7892f9ec59fbe57cbbf7dc08e942a15777e95f336ce498c73b1574f3c858cf79","title":"\u041c\u043e\u0434\u0435\u043b\u044c \u00ab\u041a\u0443\u043f\u0438 \u0441\u0435\u0439\u0447\u0430\u0441, \u043f\u043b\u0430\u0442\u0438 \u043f\u043e\u0442\u043e\u043c\u00bb \u0443\u0432\u0435\u043b\u0438\u0447\u0438\u043b\u0430 \u0441\u0440\u0435\u0434\u043d\u0438\u0439 \u0447\u0435\u043a \u043d\u0430 20%","buttonText":"","imageUuid":""}

Сегментный анализ рынка макулярной дегенерации в зависимости от возраста по методам терапии

In 2015, the global market for age-related macular degeneration was estimated at 5.335.7 million dollars. USA, and it is expected to grow by an average of 7.6% in 2016–2022.

This was during the forecast period. The global age-related maternal degeneration market is growing at a significant pace due to increased health care costs and an increased incidence of lifestyle-related diseases, such as obesity and hypertension. In addition, the current global market population at risk.

Smoking, obesity, low energy pressure, low energy, energy related to AMD. This may have symptoms.

Factors such as regulatory changes in the global market. AMD is the key age of the associated macular degeneration market.

Geographically, North America dominates the global market for age-related macular degeneration in 2015; while the Asia-Pacific market is expected during the forecast period.

Some companies are operating on the global market, Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals Inc., GlaxoSmithKline plc, StemCells Inc. and Alimera Sciences, Inc.

0
Комментарии
-3 комментариев
Раскрывать всегда